Has Deepa Manwani received payments from drug or device companies?

Yes. Drug and device makers reported $143,258 in general payments to Deepa Manwani across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Deepa Manwani did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Deepa Manwani come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Deepa Manwani

Pediatric Hematology-Oncology · Memphis, TNNPI 1922077544

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $129,210 of the $143,258 with a category attached, or 90.2%. Pfizer accounts for 66.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $42,808 and has fallen 93.1% since, to $2,968 in 2025. Among pediatric hematology-oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$143,258in general payments, 2019–2025

Across 37 payments — averaging $3871.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$96K
Novartis$31K
Global Blood Therapeutics, Inc.$11K
Novo Nordisk$4K
Novartis Pharma AG$330
Terumo BCT, Inc.$114

$1,385,849in research payments, 2019–2025

Across 109 payments — averaging $12,714 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$869K
Global Blood Therapeutics, Inc.$275K
Philips North America LLC$119K
Grifols Shared Services North America, Inc.$102K
Novo Nordisk AS$10K
Novartis Pharma AG$6K
plus $4K from 1 others

What the payments were for

Consulting fees$129,21090%
Speaking & faculty fees$3,7003%
Travel & lodging$9,8937%
Food & beverage$4560%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	18	$95,673
Novartis	7	$31,402
Global Blood Therapeutics, Inc.	7	$11,450
Novo Nordisk	3	$4,290
Novartis Pharma AG	1	$330
Terumo BCT, Inc.	1	$114

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ADAKVEO$31,732
OXBRYTA$13,676
Spectra Optia$114

How this compares

$143,258 in reported general payments places this provider in the 95th percentile of 113 pediatric hematology-oncology providers in Tennessee.

See all pediatric hematology-oncology providers in Tennessee →

Other pediatric hematology-oncology in Memphis

Scott HowardMemphis$1.5M
Ellis NeufeldMemphis$263K
Akshay SharmaMemphis$92K
Alberto PappoMemphis$88K
Ching-Hon PuiMemphis$75K
Hiroto InabaMemphis$67K
Caitlyn DuffyMemphis$50K
Amar GajjarMemphis$45K
Gary MyersMemphis$44K
Rohith JesudasMemphis$41K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →